AdaptHealth(AHCO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Full-year revenue for 2025 was $3.245 billion, a decrease of 0.5% compared to the prior year, while Q4 revenue was $846.3 million, down 1.2% year-over-year but up 1.7% on an organic basis [16][17] - Adjusted EBITDA for the full year was $616.7 million with an Adjusted EBITDA Margin of 19.0%, while Q4 Adjusted EBITDA was $163.1 million with a margin of 19.3% [19][20] - Free Cash Flow for the full year was $219.4 million, exceeding the top end of guidance [21] Business Line Data and Key Metrics Changes - Sleep Health net revenue was $372.3 million, up 4.4% year-over-year, with new starts approximately 130,600, reflecting a 6% increase [17] - Respiratory Health net revenue was $178.2 million, up 7.8% year-over-year, with oxygen and vent new starts increasing by about 4% and 5% respectively [18] - Diabetes Health net revenue was $158.5 million, down 7.4% year-over-year, with patient retention at an all-time record but new starts remaining soft [18] - Wellness at Home net revenue declined by 16.1% primarily due to the disposition of non-core assets [19] Market Data and Key Metrics Changes - Patient census records were set in Sleep Health, Respiratory Health, and Wellness at Home, with significant growth in patient numbers across these segments [4][5] - The company achieved a flat year-over-year patient census in Diabetes Health, with improved retention offsetting slower new starts [6] Company Strategy and Development Direction - The company implemented a new operating model in 2025 aimed at standardization and process maturity, which is expected to drive accelerated growth and improved financial performance in 2026 [3] - The focus remains on debt reduction and strengthening the balance sheet, with $250 million in debt reduced during the year [7][22] - The company is actively pursuing acquisitions to expand its footprint and increase patient access, while also targeting home medical equipment providers [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational foundation and strategic focus, stating that the company is in the best condition it has ever been as it enters 2026 [15] - The company anticipates revenue growth of 6%-8% for 2026, driven by new capitated agreements and organic growth [24] - Management highlighted the importance of aligning incentives in the healthcare market and the ongoing interest in capitated arrangements [44] Other Important Information - The company received favorable outcomes from CMS regarding competitive bidding, providing stability for core products [14] - A legal settlement of $14.5 million was finalized, addressing a civil debt collection class action, which management believes will de-risk the business moving forward [29][30] Q&A Session Summary Question: Clarification on the legal settlement - Management confirmed the settlement relates to a civil debt collection class action and is final, addressing all claims in that state [29][30] Question: Impact of investment on guidance and margin cadence - Management provided insights on expected revenue growth and Adjusted EBITDA margin improvements throughout 2026, with specific quarterly expectations [36][38] Question: Pipeline of capitated agreements - Management discussed ongoing conversations and market interest in capitated arrangements, emphasizing the time required to finalize such contracts [44][46] Question: Update on diabetes segment growth - Management noted improvements in retention and plans to grow the diabetes sales force to enhance new starts in 2026 [48][49] Question: Infrastructure readiness for new healthcare partnerships - Management confirmed readiness for upcoming start dates and highlighted investments made to support new capitated arrangements [52][53]